Disclaimer

Certain statements and information included herein constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. The forward-looking statements describe our expectations, plans and intentions about our business, financial condition, results of operations, cash flows and prospects.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied, in or by such forward-looking statements. Such factors include, among other things, the Company's ability to market, commercialize and achieve market acceptance of any of its products or any product candidates that it is developing or may develop in the future, and the acceptance of those products; the Company's ability to maintain an adequate sales network for its products, including its ability to attract and retain independent distributors; the effect on Medicare prescription drug coverage legislation and future legislative or regulatory reform of the health care system and its effect on the Company's ability to sell its products profitably; the Company's business strategy and underlying assumptions about market data, demographic trends, reimbursement trends, pricing trends and trends in the treatment of spine, hip and knee disorders; the Company's estimates regarding anticipated operating losses, future revenue, expenses, capital requirements, liquidity and the Company's potential need to raise additional financing; the Company's ability to comply with industry standards in regulatory compliance matters; the Company's ability to control its costs and achieve profitability; the Company's ability to market and sell its products in any international market that it attempts to enter; the Company's ability to attract and retain a qualified management team, as well as other qualified personnel and advisors; the Company's ability to enter into licensing and business combination agreements with third parties and to successfully integrate the acquired technology and/or businesses; the management team's ability to accommodate growth and manage a larger organization; the Company's ability to protect its intellectual property, and to not infringe upon the intellectual property of third parties; the Company's ability to conclude that it has effective disclosure controls and procedures; the Company's ability to comply with corporate governance programs and with changing regulations concerning corporate governance and public disclosure; and other factors contained in the Company's filings with the Securities and Exchange Commission.